Your session is about to expire
← Back to Search
EOS100850 + Immunotherapy/Chemotherapy for Cancer
Study Summary
This trial is testing a new cancer drug to see how well it works and if it has any side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- It has been over 4 weeks since my last cancer treatment.Ask your doctor for more information about joining the trial.I am 18 or older and can care for myself with minimal assistance.My advanced cancer has no standard treatments left.My organs and bone marrow are working well.I agree to have tumor biopsies before and during treatment.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What therapeutic purpose does EOS100850 typically serve?
"The drug EOS100850 is primarily used to combat malignant neoplasms and can also be employed in treating unresectable melanomas, microsatellite instability high diseases, and cancer relapse after chemotherapy."
How many volunteers are involved in this investigation?
"Affirmative. According to clinicaltrials.gov, this investigation is actively seeking participants after being first uploaded on January 28th 2019 and most recently updated on June 27th 2022. The trial requires 201 people from a single site for enrollment."
Has the FDA sanctioned EOS100850 for use?
"Our organisation assigned EOS100850 a score of 1 due to the lack of reliable information regarding its safety and efficacy - as it is currently in Phase 1."
What is the purpose of this experiment?
"This clinical experiment will span up to 15 months, with the primary goal being assessing the incidence of Dose-Limiting Toxicities in patients affected by advanced solid tumors which are administered EOS100850. Secondary objectives include determining Plasma concentration half-life (T-HALF), Maximum observed serum concentrations (Cmax) and Overall response rate per Response Evaluation Criteria In Solid Tumors (RECIST)."
Could you elaborate on the existing research surrounding EOS100850?
"Presently, there are 961 clinical trials that include EOS100850. Of these studies, 122 have advanced to the third phase of evaluation. The majority of these investigations based in Houston, Texas; however other cities around the world are hosting tests for this drug with a total of 35731 sites participating."
Are there any vacancies available to partake in this clinical trial?
"Clinicaltrials.gov attests that, as of June 27th 2022, this clinical investigation is actively seeking participants--it was initially announced on January 28th 2019."
Share this study with friends
Copy Link
Messenger